Literature DB >> 10091790

Thin cutaneous malignant melanomas (< or =1.5 mm): identification of risk factors indicative of progression.

D Massi1, A Franchi, L Borgognoni, U M Reali, M Santucci.   

Abstract

BACKGROUND: Although thin cutaneous melanomas generally have a favorable prognosis, in some cases they may undergo progression. The current study was undertaken to identify variables that may predict a more aggressive clinical outcome in these patients. In addition to classic clinicopathologic features, the authors tested the prognostic impact of three new morphometric quantitative parameters: 1) tumor thickness plus regression thickness (T+R), 2) percentage of skin thickness infiltrated by tumor cells (T/S ratio), and 3) percentage of skin thickness infiltrated by tumor cells and regression ([T+R]/S ratio).
METHODS: The authors retrospectively evaluated 287 patients with invasive cutaneous melanoma < or = 1.5 mm in thickness. Disease free survival rates (Kaplan-Meier method) were compared by using the log rank test. A multivariate analysis (Cox proportional hazards model) was used to determine the independent effect of each variable on progression. Progression was defined as any documented cutaneous local and/or distant metastasis.
RESULTS: Thirty-two of the 287 patients (11.1%) underwent disease progression. The overall 5-year and 10-year disease free survival rates were 89.3% and 84.6%, respectively. In the univariate analysis, the following factors were found to be significant predictors of progression: male gender (P = 0.01), acral-lentiginous histotype (P = 0.02), tumor thickness (P = 0.005), T+R (P = 0.001), T/S ratio > or = 50% (P = 0.03), (T+R)/S ratio > or = 50% (P = 0.006), vertical growth phase (P = 0.04), and absence of inflammatory response (P < 0.0001). Conversely, age, site, and Clark's level did not affect the risk of recurrences and/or metastases significantly. In the multivariate analysis, only T+R (P = 0.009) and inflammatory response (P < 0.0001) were found to be independent predictors of progression. Five-year disease free survival rates according to presence versus absence of inflammatory response were 93.4% and 63.8%, respectively (P < 0.0001).
CONCLUSIONS: In the current study, peritumoral and intratumoral inflammatory infiltrate and T+R were found to be strong independent predictors of progression in thin cutaneous melanomas.

Entities:  

Mesh:

Year:  1999        PMID: 10091790     DOI: 10.1002/(sici)1097-0142(19990301)85:5<1067::aid-cncr9>3.0.co;2-t

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

Review 1.  Unusual histologic and clinical variants of melanoma: implications for therapy.

Authors:  A Neil Crowson; Cynthia Magro; Martin C Mihm
Journal:  Curr Treat Options Oncol       Date:  2006-05

Review 2.  Surgery and sentinel lymph node biopsy.

Authors:  Mark B Faries; Donald L Morton
Journal:  Semin Oncol       Date:  2007-12       Impact factor: 4.929

Review 3.  Unusual histologic and clinical variants of melanoma: implications for therapy.

Authors:  A Neil Crowson; Cynthia Magro; Martin C Mihm
Journal:  Curr Oncol Rep       Date:  2007-09       Impact factor: 5.075

4.  Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram.

Authors:  Andrea Maurichi; Rosalba Miceli; Hanna Eriksson; Julia Newton-Bishop; Jérémie Nsengimana; May Chan; Andrew J Hayes; Kara Heelan; David Adams; Roberto Patuzzo; Francesco Barretta; Gianfranco Gallino; Catherine Harwood; Daniele Bergamaschi; Dorothy Bennett; Konstantinos Lasithiotakis; Paola Ghiorzo; Bruna Dalmasso; Ausilia Manganoni; Francesca Consoli; Ilaria Mattavelli; Consuelo Barbieri; Andrea Leva; Umberto Cortinovis; Vittoria Espeli; Cristina Mangas; Pietro Quaglino; Simone Ribero; Paolo Broganelli; Giovanni Pellacani; Caterina Longo; Corrado Del Forno; Lorenzo Borgognoni; Serena Sestini; Nicola Pimpinelli; Sara Fortunato; Alessandra Chiarugi; Paolo Nardini; Elena Morittu; Antonio Florita; Mara Cossa; Barbara Valeri; Massimo Milione; Giancarlo Pruneri; Odysseas Zoras; Andrea Anichini; Roberta Mortarini; Mario Santinami
Journal:  J Clin Oncol       Date:  2020-03-13       Impact factor: 44.544

5.  Retrospective Analysis of Clinicopathological Characteristics of Pregnancy Associated Melanoma.

Authors:  Melinda Fábián; Veronika Tóth; Beáta Somlai; Judit Hársing; Enikő Kuroli; Fanni Rencz; Daniella Kuzmanovszki; József Szakonyi; Béla Tóth; Sarolta Kárpáti
Journal:  Pathol Oncol Res       Date:  2015-07-16       Impact factor: 3.201

6.  Predictors of occult nodal metastasis in patients with thin melanoma.

Authors:  Mark B Faries; Leslie A Wanek; David Elashoff; Byron E Wright; Donald L Morton
Journal:  Arch Surg       Date:  2010-02

Review 7.  The changing prognosis of melanoma.

Authors:  A C Buzaid; C M Anderson
Journal:  Curr Oncol Rep       Date:  2000-07       Impact factor: 5.075

8.  Is There a Relationship Between TILs and Regression in Melanoma?

Authors:  Steven Morrison; Gang Han; Faith Elenwa; John T Vetto; Graham Fowler; Stanley P Leong; Mohammed Kashani-Sabet; Barbara Pockaj; Heidi E Kosiorek; Jonathan S Zager; Jane L Messina; Nicola Mozzillo; Schlomo Schneebaum; Dale Han
Journal:  Ann Surg Oncol       Date:  2022-01-21       Impact factor: 5.344

Review 9.  The prognostic significance of the clinical and histological parameters in primary cutaneous melanoma patients.

Authors:  Mihaela Antohe; Anastasia Coman; Gabriela Turcu; Roxana Ioana Nedelcu; Alice Brinzea; Mihaela Balaban; Andreea Moroianu; Lorena Manea; Ionela Hulea; Elena Balasescu; Sabina Andrada Zurac; Mirela Cioplea; Cristiana Popp; Luciana Nichita; Daniela Adriana Ion
Journal:  Med Pharm Rep       Date:  2022-07-26

10.  Acral lentiginous melanoma-Population, treatment, and survival using the NCDB from 2004 to 2015.

Authors:  Shelly X Bian; Lindsay Hwang; Jennifer Hwang; Omar Ragab; Gino K In; David Peng; Eugene Lin
Journal:  Pigment Cell Melanoma Res       Date:  2021-08-02       Impact factor: 4.693

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.